Immunogenicity Risk Assessment of Process-Related Impurities in An Engineered T Cell Receptor Cellular Product
- 18 May 2024
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (8) , 2151-2160
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paperMolecular Therapy - Methods & Clinical Development, 2022
- AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene TransferMolecular Therapy, 2020
- Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene deliveryPharmacology & Therapeutics, 2020
- Current In Vitro Assays for Prediction of T Cell Mediated Immunogenicity of Biotherapeutics and Manufacturing ImpuritiesJournal of Pharmaceutical Innovation, 2019
- Preclinical models to assess the immunogenicity of AAV vectorsCellular Immunology, 2019
- Gene editing: Towards the third generation of adoptive T-cell transfer therapiesImmuno-Oncology and Technology, 2019
- The Impact of Pre-existing Immunity on the Non-clinical Pharmacodynamics of AAV5-Based Gene TherapyMolecular Therapy - Methods & Clinical Development, 2019
- Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissueGene Therapy, 2012
- Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic InjectionMolecular Therapy, 2008
- T cell immune reconstitution following lymphodepletionSeminars in Immunology, 2007